1459701-35-9Relevant academic research and scientific papers
Effect of methoxy stilbenes—analogs of resveratrol—on the viability and induction of cell cycle arrest and apoptosis in human myeloid leukemia cells
Baer-Dubowska, Wanda,Kaczmarek, Mariusz,Krajka-Ku?niak, Violetta,Wierzchowski, Marcin,Zielińska-Przyjemska, Ma?gorzata
, p. 113 - 123 (2020)
The present study aimed to evaluate the cytotoxicity and its mechanism of five synthetic methoxy stilbenes, namely 3,4,4?-trimethoxy, 3,4,2?-trimethoxy, 3,4,2?,4?-tetramethoxy, 3,4,2?,6?-tetramethoxy, and 3,4,2?,4?,6?-pentamethoxy-trans-stilbenes (MS), in
3,4,2′-Trimethoxy-trans-stilbene-a potent CYP1B1 inhibitor
Mikstacka, Renata,Wierzchowski, Marcin,Dutkiewicz, Zbigniew,Gielara-Korzańska, Agnieszka,Korzański, Artur,Teubert, Anna,Sobiak, Stanis?aw,Baer-Dubowska, Wanda
, p. 496 - 501 (2014/04/17)
A novel series of methoxy-trans-stilbenes with 3,4-dimethoxy motifs was designed and synthesized. The inhibitory potency of 3,4-dimethoxystilbene derivatives against cytochrome P450 isozymes CYP1A1, CYP1B1 and CYP1A2 was evaluated. 3,4,2′-Trimethoxy-trans-stilbene (3,4,2′-TMS) exhibited extremely potent inhibitory action against CYP1B1 activity with an IC 50 of 0.004 μM. 3,4,2′-TMS exhibited 90-fold selectivity for CYP1B1 over CYP1A1 and 830-fold selectivity for CYP1B1 over CYP1A2. However, 3,4,2′,4′-tetramethoxy-trans-stilbene appeared to be the most selective inhibitor of both CYP1B1 and CYP1A1 showing very low affinity toward CYP1A2. Complementary experimental studies and computational methods were used to explain what structural determinants decide the specific affinity of stilbene derivatives to CYP1A2 and CYP1B1 binding sites.
METHOXY AND METHYLTHIO DERIVATIVES OF TRANS-STILBENE AND THEIR USE
-
Page/Page column 10, (2013/10/21)
The invention relates to the novel methoxy or methylthio derivatives of trans-stilbene and the application of new and known methoxy or methylthio derivatives of trans-stilbene as an inhibitors of cytochromes P450 of the CYP1 family in the chemopreventive formulations.
